|
(MoneyNewsWire.Net, February 18, 2016 ) Description-
Summary
GlobalDatas new report, "United Kingdom Genetic Testing Market Outlook to 2021", provides key market data on the United Kingdom Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.
Scope
- Genetic Testing market includes Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Genetic Testing market.
- Global corporate-level profiles of key companies operating within the United Kingdom Genetic Testing market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Danaher Corporation, Abbott Laboratories, Hologic, Inc., Cepheid, Bio-Rad Laboratories, Inc., Qiagen N.V., Transgenomic, Inc. and PerkinElmer, Inc.
Reasons to buy
- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution - Identify, understand and capitalize.
Table of Contents
6 Financial Deals Landscape 22
6.1 Asset Transactions 22
6.1.1 Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 22
6.2 Partnerships 24
6.2.1 Cytox Enters into Joint Development Partnership with Affymetrix 24
6.2.2 Atlas Genetics Enters into Agreement with Pharma Company 25
6.2.3 KromaTiD Enters into Distribution Agreement with Tebu-bio 26
6.2.4 Affymetrix Enters into Licensing Agreement with Peptide Groove 27
6.3 Venture Financing 28
6.3.1 Abingdon Health Raises USD3.4 Million in Venture Financing 28
7 Appendix 30
7.1 Research Methodology 31
7.1.1 Coverage 31
7.1.2 Secondary Research 31
7.1.3 Primary Research 31
7.1.4 Company Share Analysis 32
7.1.5 Distribution Share Analysis 32
7.2 GlobalData Consulting 32
7.3 Contact Us 32
7.4 Disclaimer 33
Request a Sample-http://www.researchmoz.us/enquiry.php?type=S&repid=483268
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Website: http://www.researchmoz.us
Researchmoz Global Pvt.Ltd
Researchmoz, Mr. Nachiket Ghumare
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
